Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.42 |
| ▸ | HPGD | P15428 | 5/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NPY1R | P25929 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11570722 | 0.99 | ALDH1A1 (0.43) | ALDH1A1KMT2AHPGDCYP1A2CYP3A4 | |
| SCHEMBL25139351 | 0.74 | ALDH1A1 (0.62) | ALDH1A1KMT2AHPGDALOX12MAPT | |
| SCHEMBL19399650 | 0.72 | CA3 (0.56) | ALDH1A1KMT2AHPGDALOX12SMN1; SMN2 | |
| SCHEMBL6379101 | 0.68 | ALDH1A1 (0.61) | ALDH1A1KMT2AHPGDGAASMN1; SMN2 | |
| SCHEMBL12038867 | 0.68 | ALDH1A1 (0.54) | ALDH1A1KMT2AHPGDALOX12SMN1; SMN2 | |
| SCHEMBL15022897 | 0.67 | GAA (0.54) | ALDH1A1KMT2AHPGDCYP1A2CYP2D6 | |
| SCHEMBL25139332 | 0.66 | TSHR (0.69) | ALDH1A1KMT2AHPGDALOX12SMN1; SMN2 | |
| SCHEMBL22667770 | 0.66 | ALDH1A1 (0.56) | ALDH1A1KMT2AHPGDCYP1A2CYP3A4 | |
| SCHEMBL1094537 | 0.66 | CNR1 (0.57) | CYP1A2CYP2D6CYP2C19GAAMAPT | |
| SCHEMBL5073549 | 0.66 | ALDH1A1 (0.53) | ALDH1A1KMT2AHPGDSMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230404947-A1 | COMPOSITIONS, METHODS OF TREATMENT, AND CONTAINERS INCLUDING COMPOSITIONS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-12-21 | — | — | US | disclosed |
| US-20230338310-A1 | ANTI-VIRAL THERAPY | NOVABIOTICS LIMITED (GB) | 2023-10-26 | — | — | US | disclosed |
| US-11771665-B2 | Compositions, methods of treatment, and containers including compositions | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| EP-4157247-A1 | ANTI-VIRAL THERAPY | Novabiotics Limited (GB) | 2023-04-05 | — | — | EP | disclosed |
| US-20220347126-A1 | COMPOSITIONS, METHODS OF TREATMENT, AND CONTAINERS INCLUDING COMPOSITIONS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2022-11-03 | — | — | US | disclosed |
| US-11406607-B2 | Compositions, methods of treatment, and containers including compositions | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-11369568-B2 | Microparticles comprising a sulphur-containing compound | NOVABIOTICS LIMITED (GB) | 2022-06-28 | — | — | US | disclosed |
| WO-2021240145-A1 | ANTI-VIRAL THERAPY | NOVABIOTICS LIMITED (GB) | 2021-12-02 | — | — | WO | disclosed |
| WO-2021203136-A1 | METHODS FOR TREATING HYPERPIGMENTATION AND COMPOSITIONS FOR SAME | CHEMISTRYRX (US) | 2021-10-07 | — | — | WO | disclosed |
| US-20210299019-A1 | METHODS FOR TREATING HYPERPIGMENTATION AND COMPOSITIONS FOR SAME | CHEMISTRYRX (US) | 2021-09-30 | — | — | US | disclosed |
| US-20180344671-A1 | Cysteamine as Neutrophil Elastase Inhibitor | NOVABIOTICS LIMITED (GB) | 2018-12-06 | — | — | US | disclosed |
| US-20180185305-A1 | An Amino Thiol for Use in the Treatment of an Infection Caused by the Bacterium Mycobacterium Spp | NOVABIOTICS LIMITED (GB) | 2018-07-05 | — | — | US | disclosed |
| EP-3307259-A1 | AN AMINO THIOL FOR USE IN THE TREATMENT OF AN INFECTION CAUSED BY THE BACTERIUM MYCOBACTERIUM SPP. | Novabiotics Limited (GB) | 2018-04-18 | — | — | EP | disclosed |
| WO-2017212239-A1 | TREATMENT OF DRUG-RESISTANT MICROBIAL INFECTIONS | NOVABIOTICS LIMITED (GB) | 2017-12-14 | — | — | WO | disclosed |
| US-20170348254-A1 | MICROPARTICLES | NOVABIOTICS LIMITED (GB) | 2017-12-07 | — | — | US | disclosed |
| US-20170348253-A1 | Treatment of Drug-Resistant Microbial Infections | NOVABIOTICS LIMITED (GB) | 2017-12-07 | — | — | US | disclosed |
| EP-3197476-A1 | USE OF CYSTEAMINE IN TREATING INFECTIONS CAUSED BY YEASTS/MOULDS | Novabiotics Limited (GB) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016198842-A1 | AN AMINO THIOL FOR USE IN THE TREATMENT OF AN INFECTION CAUSED BY THE BACTERIUM MYCOBACTERIUM SPP. | NOVABIOTICS LIMITED (GB) | 2016-12-15 | — | — | WO | disclosed |
| US-20160102052-A1 | Use of Cysteamine in Treating Infections caused by Yeasts/Moulds | NOVABIOTICS LIMITED (GB) | 2016-04-14 | — | — | US | disclosed |
| WO-2016046524-A1 | USE OF CYSTEAMINE IN TREATING INFECTIONS CAUSED BY YEASTS/MOULDS | NOVABIOTICS LIMITED (GB) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338310-A1 | ANTI-VIRAL THERAPY | MAVS, HAVCR2, IRF3 | GAA 227/4885ALDH1A1 2213/4885KMT2A 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.